Images List Premium Download Classic


Elan-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Cancer therapeutics
University Of Virginia Patent Foundation
August 17, 2017 - N°20170233375

This invention relates to compounds that bind to wild-type cbfβ and inhibit cbfβ binding to runx proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type cbfβ from runx1 in cells, change occupancy of runx1 on target genes, and alter gene ...
Compounds for treatment of cancer
University Of Tennessee Research Foundation
August 10, 2017 - N°20170226086

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e. G. Melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
Compounds and methods for treating cancer
Mayo Foundation For Medical Education And Research
August 10, 2017 - N°20170226073

This document provides compounds, compositions, and methods for treating cancers including renal cancer (e. G., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of scd1 to treat renal cell carcinoma (e. G., clear cell renal cell carcinoma (...
Elan Patent Pack
Download + patent application PDFs
Elan Patent Applications
Download + Elan-related PDFs
For professional research & prior art discovery
  • + full patent PDF documents of Elan-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment of melanoma by blocking benzamil sensitive ion channels/exchangers
The Board Of Trustees Of The Leland Stanford Junior University
August 10, 2017 - N°20170224683

Methods of treatment for melanoma, and compositions for use in such methods are provided. An effective dose of an agent that blocks benzamil-sensitive proteins is administered to an individual suffering from melanoma.
Drug combination to treat melanoma
Exelixis, Inc.
August 10, 2017 - N°20170224670

This invention relates to the combination of vemurafenib and the heat shock protein 90 (hsp90) inhibitor xl888 to treat melanoma, particularly braf v600 mutant melanoma in patients in need of such treatment.
Melanocortin 1 receptor ligands and methods of use
Board Of Regents, University Of Texas System
August 03, 2017 - N°20170218017

The subject invention pertains to a modified mc1r peptide ligand comprising a peptide that is a melanocortin 1 receptor (mc1r) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified mc1r peptide ligand can be coupled, e. G., via a click reaction with a complementary click functionality attached, ...
Elan Patent Pack
Download + patent application PDFs
Elan Patent Applications
Download + Elan-related PDFs
For professional research & prior art discovery
  • + full patent PDF documents of Elan-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method to diagnose malignant melanoma in the domestic dog
North Carolina State University
July 27, 2017 - N°20170211150

This disclosure is directed to the discovery of an improved method to diagnose malignant melanoma of the oral cavity in the dog.
Anti-cancer antibodies with reduced complement fixation
Merck Patent Gmbh
July 27, 2017 - N°20170210817

The invention provides modified antibodies directed against gd2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, b-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
Method for skin-whitening using composition containing resveratryl triglycolate
Merck Patent Gmbh
July 27, 2017 - N°20170210694

Since resveratryl triglycolate of the present invention can inhibit melanin synthesis and brighten skin tone, it can be effectively used as a cosmetic composition and a pharmaceutical composition for skin-whitening.
Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
Wista Laboratories Ltd.
July 27, 2017 - N°20170209456

This disclosure pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including methythioninium chloride (mtc) (also known as methylene blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (nos); nitrosyl reduction (nr); thiosulfonic ...
Skin whitening composition containing chemokine
Amorepacific Corporation
July 27, 2017 - N°20170209358

The present invention relates to a composition containing a chemokine, particularly, an interferon-inducible t-cell alpha chemoattractant (itact) which can decrease the gene expression of a factor related to melanin pigment production in melanocytes, thereby exhibiting a skin whitening effect.
P97-ids fusion proteins
Bioasis Technologies, Inc.
July 20, 2017 - N°20170204386

Provided are fusion proteins between p97 (melanotransferrin) and iduronate-2-sulfatase (ids), and related compositions and methods of use thereof, for instance, to facilitate delivery of ids across the blood-brain barrier (bbb) and/or improve its tissue penetration in cns and/or peripheral tissues, and thereby treat and/or diagnose hunter syndrome (mucopolysaccharidosis type ii; mps ii) and related lysosomal storage ...
Process for extraction of fish collagen and formulations of 3d matrices of collagen for biomedical ...
Amnivor Medicare Private Limited
July 20, 2017 - N°20170204136

Polyelectrolyte based bioactive super-absorbent material ionotropically crosslinked/neutralized involving polyvalent carboxylic acids, citrate, kojic acid, alpha arbutin along with fish scale collagen cross linked with other polyelectrolyte biopolymers preferably selected from chitosan, alginate or their combinations is used in this invention. The advancement is also directed to process of extraction of collagen of high purity from fresh water fish scale ...
Elan Patent Pack
Download + patent application PDFs
Elan Patent Applications
Download + Elan-related PDFs
For professional research & prior art discovery
  • + full patent PDF documents of Elan-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Conjugates for immunotherapy
University Of South Florida
July 20, 2017 - N°20170202902

The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a t cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the ...
Genes and gene signatures for diagnosis and treatment of melanoma
Myriad Genetics, Inc.
July 13, 2017 - N°20170198358

Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Skin lightening compounds
Wisys Technology Foundation Inc.
July 13, 2017 - N°20170197897

The present invention provides a compound of formula i, ii or iii or a salt or prodrug derivative thereof that is a skin-lightening agent useful for the inhibition of melanin synthesis and/or the removal of existing melanin to function as a skin-lightening agent.
Therapeutic and diagnostic method for ataxia-telangiectasia
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
July 13, 2017 - N°20170196871

Atm kinase is shown to regulate proteasome-mediated protein turnover through suppression of the expression of the ubiquitin-like protein isg15 (interferon stimulated gene 15). Silencing of the isg15 pathway restored both the ubiquitin and autophagy pathways, and the uv-mediated degradation of their substrates in a-t cells. The atm kinase negatively regulates the isg15 pathway, and the constitutively elevated isg15 pathway induces proteinopathy ...
Compositions and methods for fluid biopsy of melanoma
The Scripps Research Institute
July 06, 2017 - N°20170192003

The present invention provides methods for identifying circulating melanoma cells (cmcs) in a biological sample and methods for diagnosing metastatic melanoma in a subject. The methods disclosed can be used on non-enriched blood samples to identify cmc using detectable agents that are specific for a biomarker of cmcs and assessing the morphology of the cells having the detectable agents. The ...
Novel pyrrolidine compound and application as melanocortin receptor agonist
Mitsubishi Tanabe Pharma Corporation
July 06, 2017 - N°20170190697

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [i], wherein ring a represents an optionally substituted aryl group or the like; r1 represents an optionally substituted alkyl group or the like; r2 ...
Inhibitors of cyclin-dependent kinase 7 (cdk7)
Syros Pharmaceuticals, Inc.
June 29, 2017 - N°20170183355

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e. G., cancers (e. G., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and ...
Histone demethylase inhibitors
Celgene Quanticel Research, Inc.
June 29, 2017 - N°20170183325

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds. The subject compounds and compositions are useful for inhibition of at least one histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer or ...